SEARCH

SEARCH BY CITATION

References

  • 1
    Brown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011; 377: 31220.
  • 2
    Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011; 124: 194555.
  • 3
    Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011; 171: 38494.
  • 4
    Marzoll A, Melchior-Becker A, Cipollone F, et al. Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment. J Cell Mol Med. 2011; 15: 23243.
  • 5
    Hibi K, Kimura T, Kimura K, et al. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. Atherosclerosis. 2011; 219: 7439.
  • 6
    Domanski M, Coady S, Fleg J, et al. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am J Cardiol. 2007; 99: 144850.
  • 7
    Sicard P, Zeller M, Dentan G, et al. Beneficial effects of statin therapy on survival in hypertensive patients with acute myocardial infarction: data from the RICO survey. Am J Hypertens. 2007; 20: 11339.
  • 8
    Murphy SA, Cannon CP, Wiviott SD, et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009; 54: 235862.
  • 9
    Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004; 43: 6428.
  • 10
    Tehrani F, Morrissey R, Phan A, et al. Statin therapy in patients with diastolic heart failure. Clin Cardiol. 2010; 33: E15.
  • 11
    Thambidorai SK, Deshmukh AR, Walters RW, et al. Impact of statin use on heart failure mortality. Int J Cardiol. 2011; 147: 43843.
  • 12
    Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009; 373: 117582.
  • 13
    Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 208.
  • 14
    Braunwald E. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. Eur Heart J. 2012; 33: 4302.
  • 15
    Zhang WB, Du QJ, Li H, et al. The therapeutic effect of Rosuvastatin on cardiac remodeling from hypertrophy to fibrosis during the end-stage hypertension in rats. J Cell Mol Med. 2012; 16: 222737.
  • 16
    Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007; 446: 4448.
  • 17
    Shiva S, Brookes PS, Patel RP, et al. Nitric oxide partitioning into mitochondrial membranes and the control of respiration at cytochrome c oxidase. Proc Natl Acad Sci USA. 2001; 98: 72127.
  • 18
    Prabu SK, Anandatheerthavarada HK, Raza H, et al. Protein kinase A-mediated phosphorylation modulates cytochrome c oxidase function and augments hypoxia and myocardial ischemia-related injury. J Biol Chem. 2006; 281: 206170.
  • 19
    Atkinson J, Poitevin P, Chillon JM, et al. Vascular Ca overload produced by vitamin D3 plus nicotine diminishes arterial distensibility in rats. Am J Physiol. 1994; 266: H5407.
  • 20
    Hu X, Li T, Zhang C, et al. GATA4 regulates ANF expression synergistically with Sp1 in a cardiac hypertrophy model. J Cell Mol Med. 2011; 15: 186577.
  • 21
    Susic D, Varagic J, Ahn J, et al. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol. 2003; 42: 10917.
  • 22
    Loch D, Levick S, Hoey A, et al. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol. 2006; 47: 396404.
  • 23
    Saka M, Obata K, Ichihara S, et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol. 2006; 47: 7709.
  • 24
    Prandin MG, Cicero AF, Dormi A, et al. Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practice. Nutr Metab Cardiovasc Dis. 2010; 20: 5128.
  • 25
    Jarai R, Kaun C, Weiss TW, et al. Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1alpha, tumour necrosis factor-alpha and transforming growth factor-beta. J Cell Mol Med. 2009; 13: 441521.
  • 26
    Florkowski CM, Molyneux SL, George PM. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2008; 358: 1301.
  • 27
    Chang SA, Kim YJ, Lee HW, et al. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Hypertension. 2009; 54: 5917.
  • 28
    Hambleton M, Hahn H, Pleger ST, et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation. 2006; 114: 57482.
  • 29
    Belmonte SL, Blaxall BC. PKC-ing is believing: targeting protein kinase C in heart failure. Circ Res. 2011; 109: 13202.
  • 30
    Palaniyandi SS, Sun L, Ferreira JC, et al. Protein kinase C in heart failure: a therapeutic target. Cardiovasc Res. 2009; 82: 22939.
  • 31
    Qvit N, Mochly-Rosen D. Highly specific modulators of protein kinase C localization: applications to heart failure. Drug Discov Today Dis Mech. 2010; 7: e8787e93.
  • 32
    Palaniyandi SS, Ferreira JC, Brum PC, et al. PKCbetaII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fibrosis and pro-inflammatory responses. J Cell Mol Med. 2011; 15: 176977.
  • 33
    Inagaki K, Koyanagi T, Berry NC, et al. Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. Hypertension. 2008; 51: 15659.
  • 34
    Liu Q, Chen X, Macdonnell SM, et al. Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res. 2009; 105: 194200.
  • 35
    Macrez N, Morel JL, Kalkbrenner F, et al. A betagamma dimer derived from G13 transduces the angiotensin AT1 receptor signal to stimulation of Ca2 +  channels in rat portal vein myocytes. J Biol Chem. 1997; 272: 231805.
  • 36
    Ushio-Fukai M, Griendling KK, Akers M, et al. Temporal dispersion of activation of phospholipase C-beta1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. J Biol Chem. 1998; 273: 197727.
  • 37
    Hansen JL, Theilade J, Haunso S, et al. Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation. J Biol Chem. 2004; 279: 2410815.
  • 38
    Rodriguez P, Mitton B, Waggoner JR, et al. Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J Biol Chem. 2006; 281: 38599608.
  • 39
    Sahin B, Shu H, Fernandez J, et al. Phosphorylation of protein phosphatase inhibitor-1 by protein kinase C. J Biol Chem. 2006; 281: 2432235.
  • 40
    Louch WE, Hougen K, Mork HK, et al. Sodium accumulation promotes diastolic dysfunction in end-stage heart failure following Serca2 knockout. J Physiol. 2010; 588: 46578.
  • 41
    Niwano K, Arai M, Koitabashi N, et al. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther. 2008; 16: 102632.
  • 42
    Revenco D, Morgan JP. Metabolic modulation and cellular therapy of cardiac dysfunction and failure. J Cell Mol Med. 2009; 13: 81125.
  • 43
    Tateishi K, Takehara N, Matsubara H, et al. Stemming heart failure with cardiac- or reprogrammed-stem cells. J Cell Mol Med. 2008; 12: 221732.
  • 44
    Gruenbacher G, Gander H, Nussbaumer O, et al. IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56 +  dendritic cells. Cancer Res. 2010; 70: 961120.
  • 45
    Kwok SC, Samuel SP, Handal J. Atorvastatin activates heme oxygenase-1 at the stress response elements. J Cell Mol Med. 2012; 16: 394400.
  • 46
    Steinmetz M, Brouwers C, Nickenig G, et al. Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells. J Cell Mol Med. 2010; 14: 164556.